A Clinical Trial to Evaluate the Effectiveness and Safety of Xiyanping Injection in the Treatment of Mild Type of Hand, Foot, and Mouth Disease

Overview

The aim of this study is to evaluate the effectiveness and safety of Xiyanping Injection for mild type of hand, foot, and mouth disease.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: May 2011

Detailed Description

By adopting a multi-center, randomized and controlled clinical trial, this study is aimed to evaluate the efficacy and safety of Xiyanping Injection in the treatment of mild type of Hand, Foot and Mouth Disease (HFMD), and designed to combine both observational and interventional methodologies in this research.

Interventions

  • Other: Western therapy
    • Symptomatic treatment: vitamin B, vitamin C, mouth care and skin care. Adopting physical cooling therapy, including physical cooling paste or warm bathing, when patient’s body temperature is lower than 38.5 degree Celsius; Using Ibuprofen suspension when patient’s temperature higher than 38.5 degree Celsius;
  • Drug: Xiyanping Injection
    • Dosage for child medication: 5-10mg/kg/d (0.2-0.4ml/kg/d) in 5% Glucose solution, IV, with speed of 20-30 drops per minute, each day; or as directed by doctor.
  • Drug: Xiyanping Injection with western medicine
    • Symptomatic treatment using the same treatment methods in western therapy group; Symptomatic treatment using the same treatment methods in Xiyanpin injection group.

Arms, Groups and Cohorts

  • Active Comparator: Western therapy
  • Experimental: Xiyanping Injection
  • Experimental: Xiyanping Injection with western medicine

Clinical Trial Outcome Measures

Primary Measures

  • time of bringing down the fever
    • Time Frame: 10 days
    • Refering to the length of time to bring down the fever by 0.5 degrees Celsius after the medicine is taken.
  • time of body temperature going back to normal
    • Time Frame: 10 days
    • Refering to the time of the armpit temperature of lower than 37.0 degrees Celsius, lasting for at least 24 hours, after the medicine is taken.

Secondary Measures

  • time of symptom disappearance
    • Time Frame: 10 days
    • Refering to the length of time when clinical symptoms and signs totally disappere after the medicine is used.
  • case severity rate
    • Time Frame: 10 days
    • Refering to the ratio of patient with mild type of HFMD to severe type, such as damage of central nervous system, pulmonary edema, heart failure, respiratory failure, etc.
  • time of tetter disappearance
    • Time Frame: 10 days
    • Refering to the length of time when the tetter due to HFMD disappears, characterised by scab(s) or dropping; and time of oral ulcer concrescence, etc.
  • direct medical cost
    • Time Frame: 10 days
    • Referring to the costs in the treatment of HFMD and relative disease, including the registration fee, examination fee, and drug fees, etc.
  • safety outcome
    • Time Frame: 10 days
    • Calculated by adverse event.

Participating in This Clinical Trial

Inclusion Criteria

  • Clinical diagnosis of severe hand-foot-mouth disease patients according to Hand-Foot-Mouth Disease Treatment Guidelines 2010 issued by China's Ministry of Health; More than 1/3 patients should be diagnosed by etiological examination.
  • Less than 48 hours of occurrence of fever and/or occurrence of tetter or herpes.
  • Age of 1-14 years.
  • Patients or their guardians agree to participate in this study and signed the informed consent form.

Exclusion Criteria

  • Complicated with other serious primary diseases in organ such as congenital heart disease, chronic hepatitis, nephritis and blood diseases, etc.
  • With history of allergies on traditional Chinese medicine.
  • Patients or their guardians suffering from Psychiatric diseases.
  • Attending other clinical studies on HFMD after diagnosed.

Gender Eligibility: All

Minimum Age: 1 Year

Maximum Age: 14 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine
  • Collaborator
    • Beijing University of Chinese Medicine
  • Provider of Information About this Clinical Study
    • Guoliang Zhang, The First Affiliated Hospital of Anhui College of Traditional Chinese Medicine
  • Overall Official(s)
    • Guoliang Zhang, Principal Investigator, An’Hui Chinese Medical College Affiliated No.1 Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.